

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTACDR1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUIDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAPLUS and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS EXPRESS	FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008		
NEWS HOURS	STN Operating Hours Plus Help Desk Availability		
NEWS LOGIN	Welcome Banner and News Items		
NEWS IPC8	For general information regarding STN implementation of IPC 8		

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:54:10 ON 04 JUN 2008

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 14:54:45 ON 04 JUN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 JUN 2008 HIGHEST RN 1025148-33-7

DICTIONARY FILE UPDATES: 3 JUN 2008 HIGHEST RN 1025148-33-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10566094a.str



chain nodes :

10 11 12 13 14

ring nodes :

1 2 3 4 5 6 7 8 9

chain bonds :

2-11 7-14 10-14 11-12 12-13

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9

exact/norm bonds :

2-11 5-7 6-9 7-8 7-14 8-9 10-14 11-12

exact bonds :

12-13

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS


11:CLASS 12:CLASS 13:Atom 14:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 14:55:18 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1091 TO ITERATE

100.0% PROCESSED 1091 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 19839 TO 23801

PROJECTED ANSWERS: 2 TO 124


L2 2 SEA SSS SAM L1

=> d scan

L2 2 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN Benzenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-2-methyl-1H-indol-5-yl]-4-phenoxy-

MF C25 H27 N3 O3 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

```
L2 2 ANSWERS  REGISTRY  COPYRIGHT 2008 ACS on STN
IN Glycinamide, N-[6-[5-[[ (4-fluorophenyl)sulfonyl]amino]-2-phenyl-1H-indol-1-
MF C30 H30 F N5 O6 S
```

PAGE 1-A



PAGE 1-B

$$\text{—NH}_2$$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

```
=> s ll sss full
FULL SEARCH INITIATED 14:56:29 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      21961 TO ITERATE
```

```
100.0% PROCESSED      21961 ITERATIONS                      36 ANSWERS
SEARCH TIME: 00.00.01
```

L3 36 SEA SSS FUL L1

```
=> file caplus
```

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	179.28	179.49

FILE 'CAPLUS' ENTERED AT 14:56:38 ON 04 JUN 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Jun 2008 VOL 148 ISS 23
 FILE LAST UPDATED: 3 Jun 2008 (20080603/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s 13

L4 6 L3

=> d ibib abs hitstr 6

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:725572 CAPLUS

DOCUMENT NUMBER: 142:211383

TITLE: Medicinal Chemistry Driven Approaches Toward Novel and Selective Serotonin 5-HT6 Receptor Ligands
 AUTHOR(S): Holenz, Joerg; Merce, Ramon; Diaz, Jose Luis; Guitart, Xavier; Codony, Xavier; Dordal, Alberto; Romero, Gonzalo; Torrens, Antoni; Mas, Josep; Andaluz, Blas; Hernandez, Susana; Monroy, Xavier; Sanchez, Elisabeth; Hernandez, Enrique; Perez, Raquel; Cubi, Roger; Sanfeliu, Olga; Buschmann, Helmut

CORPORATE SOURCE: Departments of Medicinal Chemistry, Discovery Biology and Discovery Chemistry, Laboratorios Dr. Esteve S.A., Barcelona, 08041, Spain

SOURCE: Journal of Medicinal Chemistry (2005), 48(6), 1781-1795

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 142:211383

AB Based on a medicinal chemical guided hypothetical pharmacophore model, novel series of indolyl sulfonamides have been designed and prepared as selective and high-affinity serotonin 5-HT6 receptor ligands. Furthermore, based on a screening approach of a discovery library, a series of benzoxazinepiperidiny sulfonamides were identified as selective 5-HT6 ligands. Many of the compds. described in this paper possess excellent affinities, displaying pKi values greater than 8 (some even >9) and high selectivities against a wide range (>50) of other CNS relevant receptors.

First, structure-affinity relationships of these ligands are discussed. In terms of functionality, high-affinity antagonists, as well as agonists and even partial agonists, were prepared. Compds. 19c and 19g represent the highest-affinity 5-HT₆ agonists ever reported in the literature. These valuable tool compds. should allow for the detailed study of the role of the 5-HT₆ receptor in relevant animal models of disorders such as cognition deficits, depression, anxiety, or obesity.


IT 753020-75-6P 753020-76-7P 753020-79-0P
753020-80-3P 753020-82-5P 753020-83-6P
753020-84-7P

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(medicinal chemical driven approaches toward novel and selective serotonin 5-HT₆ receptor ligands)


RN 753020-75-6 CAPLUS

CN 1-Naphthalenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-
(CA INDEX NAME)




RN 753020-76-7 CAPLUS

CN 2-Naphthalenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-
(CA INDEX NAME)



RN 753020-79-0 CAPLUS


CN 1-Naphthalenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-2-methyl-1H-indol-5-yl]-
(CA INDEX NAME)



RN 753020-80-3 CAPLUS


CN 2-Naphthalenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-2-methyl-1H-indol-5-yl]-

5-yl]- (CA INDEX NAME)




RN 753020-82-5 CAPLUS

CN 1-Naphthalenesulfonamide, N-[1-[2-(diethylamino)ethyl]-1H-indol-5-yl]-
(CA INDEX NAME)




RN 753020-83-6 CAPLUS

CN 2-Naphthalenesulfonamide, N-[1-[2-(diethylamino)ethyl]-1H-indol-5-yl]-
(CA INDEX NAME)



RN 753020-84-7 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-[1-[2-(diethylamino)ethyl]-1H-indol-5-yl]-
(CA INDEX NAME)



REFERENCE COUNT:

68

THERE ARE 68 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d ibib abs hitstr 1-5

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:197836 CAPLUS

DOCUMENT NUMBER: 146:252104
 TITLE: Preparation of substituted indoles and their use as PAI-1 inhibitors
 INVENTOR(S): Hu, Baihua; Jetter, James W.
 PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
 SOURCE: PCT Int. Appl., 54pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007022321	A2	20070222	WO 2006-US32066	20060816
WO 2007022321	A3	20070510		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA AU 2006279496 A1 20070222 AU 2006-279496 20060816 CA 2617372 A1 20070222 CA 2006-2617372 20060816 US 20070043101 A1 20070222 US 2006-505527 20060816 EP 1919866 A2 20080514 EP 2006-801683 20060816 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR PRIORITY APPLN. INFO.: US 2005-708834P P 20050817 WO 2006-US32066 W 20060816 OTHER SOURCE(S): MARPAT 146:252104 GI				



I


AB The invention relates to indole derivs. I [R is p-R₂C₆H₄(CH₂)₁₋₄, where R₂ is alkyl, and R₁ is a sulfonylamino or ureido group; or R is R₃C₆H₄(CH₂)₀₋₄CHR₄, where R₃ is H, a carboxyalkoxy, carbamoyl, or carbonyl-amino acid group and R₄ is H, CO₂H, or CONHNH₂ and R₁ is a sulfonylamino group; or R is R₅CO(CH₂)₁₋₄, where R₅ is OH, alkoxy, or an amino acid residue and R₁ is a sulfonylamino group] for use as PAI-1 inhibitors. Thus, N-[[[1-(4-tert-butylbenzyl)-1H-indol-5-yl]amino]carbonyl]-L-phenylalanine was prepared by treating 1-(4-tert-butylbenzyl)-1H-indol-5-amine (preparation given) with 2-isocyanato-3-phenylpropionic acid Et ester.

IT 926024-84-2P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of substituted indoles and their use as PAI-1 inhibitors)
 RN 926024-84-2 CAPLUS
 CN 1H-Indole-1-acetic acid, α -(phenylmethyl)-5-[[[4-(trifluoromethoxy)phenyl]sulfonyl]amino]-, hydrazide (CA INDEX NAME)




IT 926024-62-6P 926024-64-8P 926024-66-0P
 926024-68-2P 926024-70-6P 926024-74-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of substituted indoles and their use as PAI-1 inhibitors)
 RN 926024-62-6 CAPLUS
 CN L-Phenylalanine, N-[2-[5-[[[1,1'-biphenyl]-4-ylsulfonyl]amino]-1H-indol-1-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 926024-64-8 CAPLUS
 CN L-Phenylalanine, N-[2-[5-[[[4-(1,1-dimethylethyl)phenyl]sulfonyl]amino]-1H-indol-1-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 926024-66-0 CAPLUS

CN L-Leucine, N-[2-[5-[[[1,1'-biphenyl]-4-ylsulfonyl]amino]-1H-indol-1-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 926024-68-2 CAPLUS

CN L-Leucine, N-[2-[5-[[[4-(1,1-dimethylethyl)phenyl]sulfonyl]amino]-1H-indol-1-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 926024-70-6 CAPLUS

CN L-Phenylalanine, N-[2-[5-[[[4-(trifluoromethoxy)phenyl]sulfonyl]amino]-1H-indol-1-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 926024-74-0 CAPLUS

CN L-Leucine, N-[2-[5-[[[4-(trifluoromethoxy)phenyl]sulfonyl]amino]-1H-indol-1-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:1244611 CAPLUS

DOCUMENT NUMBER: 146:142447

TITLE: An engineered linker capable of promoting on-resin reactions for microwave-assisted solid-phase organic synthesis

AUTHOR(S): Sun, Li-Ping; Dai, Wei-Min

CORPORATE SOURCE: Department of Chemistry, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong

SOURCE: Angewandte Chemie, International Edition (2006), 45(43), 7255-7258

CODEN: ACIEF5; ISSN: 1433-7851

PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 146:142447

AB A diglycine-containing linker was fabricated on Rink amide resin for dual functions: a) attachment of a scaffold and b) capture of metal ions for promoting on-resin reactions. The metal-catching feature of the linker proves essential for the solid-phase synthesis of indoles through microwave-assisted CuII-mediated heteroannulation.

IT 919490-32-7P 919490-34-9P 919490-36-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(microwave-assisted copper-mediated solid-phase synthesis of (arylsulfonylamino)indoles using diglycine-containing linker capable of catching metal ions and promoting on-resin reactions)


RN 919490-32-7 CAPLUS

CN Glycinamide, N-[6-[2-(4-methoxyphenyl)-5-[[[4-(1-methylethyl)phenyl]sulfonyl]amino]-1H-indol-1-yl]-1,6-dioxohexyl]glycyl- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 919490-34-9 CAPLUS

CN Glycinamide, N-[6-[5-[[[(4-fluorophenyl)sulfonyl]amino]-2-phenyl-1H-indol-1-yl]-1,6-dioxohexyl]glycyl- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 919490-36-1 CAPLUS

CN Glycinamide, N-[6-[2-butyl-5-[[[(4-fluorophenyl)sulfonyl]amino]-1H-indol-1-yl]-1,6-dioxohexyl]glycyl- (CA INDEX NAME)

PAGE 1-A




—NH₂

IT 919490-25-8P 919490-27-0P 919490-28-1P
919490-30-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(microwave-assisted copper-mediated solid-phase synthesis of
(arylsulfonylamino)indoles using diglycine-containing linker capable of
catching metal ions and promoting on-resin reactions)


RN 919490-25-8 CAPLUS

CN Glycinamide, N-[6-[5-[[[(4-fluorophenyl)sulfonyl]amino]-2-(4-methoxyphenyl)-
1H-indol-1-yl]-1,6-dioxohexyl]glycyl- (CA INDEX NAME)

—NH₂

RN 919490-27-0 CAPLUS


CN 1H-Indole-1-hexanamide, N-(2-amino-2-oxoethyl)-2-butyl-5-[[[(4-methoxyphenyl)sulfonyl]amino]-ε-oxo- (CA INDEX NAME)




RN 919490-28-1 CAPLUS

CN Glycinamide, N-[6-[2-butyl-5-[[(4-methoxyphenyl) sulfonyl] amino]-1H-indol-1-yl]-1,6-dioxohexyl]glycyl- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 919490-30-5 CAPLUS

CN Glycinamide, N-[6-[2-butyl-5-[[(4-methoxyphenyl) sulfonyl] amino]-1H-indol-1-yl]-1,6-dioxohexyl]glycylglycyl- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:136598 CAPLUS

DOCUMENT NUMBER: 142:240323

TITLE: Active substance combination comprising a compound

with NPY receptor affinity and a compound with 5-HT6 receptor affinity

INVENTOR(S): Torrens Jover, Antoni; Mas Prio, Josep; Dordal Zuera, Alberto; Codony Soler, Xavier; Merce Vidal, Ramon; Aurelio Castrillo Perez, Jose; Frigola Constansa, Jordi; Buschmann, Helmut-Heinrich

PATENT ASSIGNEE(S): Laboratorios del Esteve S. A., Spain

SOURCE: PCT Int. Appl., 427 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005014045	A1	20050217	WO 2004-EP8514	20040729
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
ES 2228268	A1	20050401	ES 2003-1815	20030730
ES 2228268	B1	20060701		
AU 2004262488	A1	20050217	AU 2004-262488	20040729
CA 2534099	A1	20050217	CA 2004-2534099	20040729
EP 1660131	A1	20060531	EP 2004-741321	20040729
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
MX 2006PA01230	A	20060515	MX 2006-PA1230	20060130
US 20070009597	A1	20070111	US 2006-566402	20060705
PRIORITY APPLN. INFO.:			ES 2003-1815	A 20030730
			WO 2004-EP8514	W 20040729
OTHER SOURCE(S):			CASREACT 142:240323; MARPAT 142:240323	
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to an active substance combination comprising at least one compound I [R1-R4 = H, halo, alkyl, etc.; R5 = H, alkyl, (un)saturated cycloalkyl; R6-R9 = H, alkyl, (un)saturated cycloalkyl, etc.];

A = CHR18, CHR18CH2; B = alkyl, (un)saturated cycloalkyl, etc.; R10 = H, alkyl, (un)saturated cycloalkyl, etc.; R11 = alkyl, (un)saturated cycloalkyl, etc.; NR10R11 = (un)saturated heterocyclyl; R18 = H, alkyl, (un)saturated cycloalkyl, etc.] with neuropeptide Y-receptor affinity, preferably neuropeptide Y5-receptor affinity, and at least one compound with 5-HT6 receptor affinity (such as II [R1 = H, alkyl, Ph, CH2PH; R2 = NR4R5, (un)saturated (hetero)cycloalkyl, etc.; R3 = H, alkyl; R4, R5 = H, alkyl; or NR4R5 = (un)saturated heterocyclyl; A = (un)substituted (hetero)aryl; n = 0-4]), a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament. Synthesis of amides I and sulfonamides such as II is described in

examples. E.g., a multi-step synthesis of III.HCl, starting from 1-(tert-butoxycarbonyl)-4-piperidinone and Me anthranilate, was given. The amides I and sulfonamides such as II were tested against neuropeptide Y5 and 5-HT6 binding (data given for representative compds.).


IT 753020-75-6P 753020-76-7P 753020-79-0P
 753020-80-3P 753020-82-5P 753020-83-6P
 753020-84-7P 844831-85-2P 844831-86-3P
 844831-88-5P 844831-89-6P 844831-92-1P
 844831-93-2P 844831-94-3P 844832-00-4P
 844832-01-5P 844832-02-6P 844832-04-8P
 844832-05-9P 844832-07-1P 844832-09-3P
 844832-10-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amides and sulfonamides as components of active combination with NPY receptor affinity and 5-HT6 receptor affinity)


RN 753020-75-6 CAPLUS

CN 1-Naphthalenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]- (CA INDEX NAME)




RN 753020-76-7 CAPLUS

CN 2-Naphthalenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]- (CA INDEX NAME)




RN 753020-79-0 CAPLUS


CN 1-Naphthalenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-2-methyl-1H-indol-5-yl]- (CA INDEX NAME)




RN 753020-80-3 CAPLUS
 CN 2-Naphthalenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-2-methyl-1H-indol-5-yl]- (CA INDEX NAME)




RN 753020-82-5 CAPLUS
 CN 1-Naphthalenesulfonamide, N-[1-[2-(diethylamino)ethyl]-1H-indol-5-yl]- (CA INDEX NAME)




RN 753020-83-6 CAPLUS
 CN 2-Naphthalenesulfonamide, N-[1-[2-(diethylamino)ethyl]-1H-indol-5-yl]- (CA INDEX NAME)



RN 753020-84-7 CAPLUS
 CN [1,1'-Biphenyl]-4-sulfonamide, N-[1-[2-(diethylamino)ethyl]-1H-indol-5-yl]- (CA INDEX NAME)




RN 844831-85-2 CAPLUS
 CN 1-Naphthalenesulfonamide, 5-chloro-N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]- (CA INDEX NAME)




RN 844831-86-3 CAPLUS

CN Benzenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]- (CA INDEX NAME)




RN 844831-88-5 CAPLUS

CN Benzenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-4-phenoxy- (CA INDEX NAME)




RN 844831-89-6 CAPLUS

CN Benzenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-4-methyl- (CA INDEX NAME)




RN 844831-92-1 CAPLUS

CN Benzenesulfonamide, 3,5-dichloro-N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]- (CA INDEX NAME)




RN 844831-93-2 CAPLUS

CN Benzenesulfonamide, 3-bromo-N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-
(CA INDEX NAME)




RN 844831-94-3 CAPLUS

CN Benzenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-2-nitro-
(CA INDEX NAME)




RN 844832-00-4 CAPLUS

CN Benzenesulfonamide, 4-acetyl-N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-
(CA INDEX NAME)




RN 844832-01-5 CAPLUS

CN Benzenesulfonamide, 4-bromo-N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-
(CA INDEX NAME)




RN 844832-02-6 CAPLUS

CN Benzenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-4-methoxy-
(CA INDEX NAME)




RN 844832-04-8 CAPLUS

CN Benzenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-4-nitro-
(CA INDEX NAME)




RN 844832-05-9 CAPLUS

CN Benzenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-4-fluoro-
(CA INDEX NAME)




RN 844832-07-1 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, N-[1-[2-(dimethylamino)ethyl]-2-methyl-1H-indol-5-yl]-
(CA INDEX NAME)



RN 844832-09-3 CAPLUS
 CN Benzenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-2-methyl-1H-indol-5-yl]-4-phenoxy- (CA INDEX NAME)



RN 844832-10-6 CAPLUS
 CN Benzenesulfonamide, 3,5-dichloro-N-[1-[2-(dimethylamino)ethyl]-2-methyl-1H-indol-5-yl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:136568 CAPLUS

DOCUMENT NUMBER: 142:240322

TITLE: Active substance combination comprising a compound with NPY receptor affinity and a compound with 5-HT6 receptor affinity

INVENTOR(S): Torrens Jover, Antoni; Mas Prio, Josep; Dordal Zueras, Alberto; Codony Soler, Xavier; Merce Vidal, Ramon; Aurelio Castrillo Perez, Jose; Frigola Constansa, Jordi; Buschmann, Helmut-Heinrich

PATENT ASSIGNEE(S): Laboratorios del Esteve S. A., Spain

SOURCE: PCT Int. Appl., 451 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 2005014000	A1	20050217	WO 2004-EP8515	20040729
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
ES 2228267	A1	20050401	ES 2003-1814	20030730
ES 2228267	B1	20060701		
AU 2004262489	A1	20050217	AU 2004-262489	20040729
CA 2534100	A1	20050217	CA 2004-2534100	20040729
EP 1648468	A1	20060426	EP 2004-763612	20040729
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
MX 2006PA01232	A	20060515	MX 2006-PA1232	20060130
US 20070059364	A1	20070315	US 2006-566100	20061026
PRIORITY APPLN. INFO.:			ES 2003-1814	A 20030730
			WO 2004-EP8515	W 20040729
OTHER SOURCE(S):	MARPAT 142:240322			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The present invention relates to an active substance combination comprising at least one compound I [R1-R4 = H, halo, alkyl, etc.; R5 = H, alkyl, (un)saturated (hetero)cycloalkyl; R6-R9 = H, alkyl, (un)saturated (hetero)cycloalkyl, etc.; A = CHR18, CHR18CH2; R10 = H, alkyl, (un)saturated cycloalkyl, etc.; R11 = alkyl, (un)saturated cycloalkyl, etc.; NR10R11 = (un)saturated heterocyclyl; R18 = H, alkyl, (un)saturated cycloalkyl, etc.] with neuropeptide Y-receptor affinity, preferably neuropeptide Y5-receptor affinity, and at least one compound with 5-HT6 receptor affinity (such as II [R1 = H, alkyl, Ph, CH2PH; R2 = NR4R5, (un)saturated (hetero)cycloalkyl, etc.; R3 = H, alkyl; R4, R5 = H, alkyl; or NR4R5 = (un)saturated heterocyclyl; A = (un)substituted (hetero)aryl; n = 0-4]), a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament. Synthesis of amides I and sulfonamides such as II is described in examples. Thus, reacting 6-chloro-1-(4-piperidinyl)-1,4-dihydro-2H-3,1-benzoxazinone hydrochloride with 2-(2-chloroacetamide)-2',5-dichlorobenzophenone in the presence of K2CO3 in DMF followed by treating of the free base with HCl/EtOH afforded 61% III.HCl. The amides I and sulfonamides such as II were tested against neuropeptide Y5 and 5-HT6 binding (data given for representative compds.).

IT 753020-75-6P 753020-76-7P 753020-79-0P
753020-80-3P 753020-82-5P 753020-83-6P
753020-84-7P 844831-85-2P 844831-86-3P
844831-88-5P 844831-89-6P 844831-92-1P
844831-93-2P 844831-94-3P 844832-00-4P
844832-01-5P 844832-02-6P 844832-04-8P
844832-05-9P 844832-07-1P 844832-09-3P
844832-10-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amides and sulfonamides as components of active combination
with NPY receptor affinity and 5-HT₆ receptor affinity)


RN 753020-75-6 CAPLUS

CN 1-Naphthalenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-
(CA INDEX NAME)




RN 753020-76-7 CAPLUS

CN 2-Naphthalenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-
(CA INDEX NAME)




RN 753020-79-0 CAPLUS

CN 1-Naphthalenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-2-methyl-1H-indol-5-yl]-
(CA INDEX NAME)



RN 753020-80-3 CAPLUS


CN 2-Naphthalenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-2-methyl-1H-indol-5-yl]-
(CA INDEX NAME)



RN 753020-82-5 CAPLUS


CN 1-Naphthalenesulfonamide, N-[1-[2-(diethylamino)ethyl]-1H-indol-5-yl]-

(CA INDEX NAME)




RN 753020-83-6 CAPLUS

CN 2-Naphthalenesulfonamide, N-[1-[2-(diethylamino)ethyl]-1H-indol-5-yl]-
(CA INDEX NAME)




RN 753020-84-7 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-[1-[2-(diethylamino)ethyl]-1H-indol-5-yl]-
(CA INDEX NAME)




RN 844831-85-2 CAPLUS

CN 1-Naphthalenesulfonamide, 5-chloro-N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-
(CA INDEX NAME)




RN 844831-86-3 CAPLUS

CN Benzenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]- (CA
INDEX NAME)




RN 844831-88-5 CAPLUS

CN Benzenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-4-phenoxy-
(CA INDEX NAME)




RN 844831-89-6 CAPLUS

CN Benzenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-4-methyl-
(CA INDEX NAME)




RN 844831-92-1 CAPLUS

CN Benzenesulfonamide, 3,5-dichloro-N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-
(CA INDEX NAME)




RN 844831-93-2 CAPLUS

CN Benzenesulfonamide, 3-bromo-N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-
(CA INDEX NAME)




RN 844831-94-3 CAPLUS

CN Benzenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-2-nitro-
(CA INDEX NAME)




RN 844832-00-4 CAPLUS

CN Benzenesulfonamide, 4-acetyl-N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-
(CA INDEX NAME)




RN 844832-01-5 CAPLUS

CN Benzenesulfonamide, 4-bromo-N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-
(CA INDEX NAME)




RN 844832-02-6 CAPLUS

CN Benzenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-4-methoxy-
(CA INDEX NAME)




RN 844832-04-8 CAPLUS

CN Benzenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-4-nitro-
(CA INDEX NAME)




RN 844832-05-9 CAPLUS

CN Benzenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-4-fluoro-
(CA INDEX NAME)




RN 844832-07-1 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-[1-[2-(dimethylamino)ethyl]-2-methyl-1H-indol-5-yl]-
(CA INDEX NAME)




RN 844832-09-3 CAPLUS

CN Benzenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-2-methyl-1H-indol-5-yl]-
4-phenoxy- (CA INDEX NAME)



RN 844832-10-6 CAPLUS

CN Benzenesulfonamide, 3,5-dichloro-N-[1-[2-(dimethylamino)ethyl]-2-methyl-1H-indol-5-yl]- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:136549 CAPLUS

DOCUMENT NUMBER: 142:240310

TITLE: Preparation of indol-5-yl sulfonamide derivatives and their use as 5-HT6 modulators

INVENTOR(S): Merce Vidal, Ramon; Codony Soler, Xavier; Dordal Zuera, Alberto

PATENT ASSIGNEE(S): Laboratorios del Esteve S. A., Spain

SOURCE: PCT Int. Appl., 123 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005013977	A1	20050217	WO 2004-EP8511	20040729
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
ES 2222827	A1	20050201	ES 2003-1805	20030730
ES 2222827	B1	20060301		
AU 2004262485	A1	20050217	AU 2004-262485	20040729
CA 2533976	A1	20050217	CA 2004-2533976	20040729
EP 1648445	A1	20060426	EP 2004-763610	20040729

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

CN 1832740	A	20060913	CN 2004-80022472	20040729
BR 2004013110	A	20061003	BR 2004-13110	20040729
JP 2007500165	T	20070111	JP 2006-521529	20040729
MX 2006PA01159	A	20060424	MX 2006-PA1159	20060127
NO 2006000865	A	20060222	NO 2006-865	20060222
US 20070032520	A1	20070208	US 2006-566094	20061003

PRIORITY APPLN. INFO.: ES 2003-1805 A 20030730
 WO 2004-EP8511 W 20040729

OTHER SOURCE(S): CASREACT 142:240310; MARPAT 142:240310
 GI




AB Title compds. I [R1 = NR8R9 radical or (un)saturated-(un)substituted cycloaliph. radical optionally containing at least one heteroatom; R2-4,6-7 independently = H, NO2, alkoxy, CN, etc.; R5 = H or (un)saturated alkyl optionally at least monosubstituted; R8 or R9 independently = H or (un)saturated alkyl optionally at least monosubstituted with provisions; or R8 and R9 together with the bridging N atom form a (un)saturated-(un)substituted heterocyclic ring; A = (un)substituted mono or polycyclic aromatic ring; n = 0-4] and their pharmaceutically acceptable salts are prepared and disclosed as 5-HT6 modulators. Thus, e.g., II, was prepared via reaction of naphthalene-2-sulfonyl chloride with 5-amino-1-(2-dimethylaminoethyl)-1H-indole. Selected data from 5-HT6 receptor binding studies revealed Ki values (nM) ranging from 1.89-112.4.

IT 753020-75-6P 753020-76-7P 753020-79-0P
 753020-80-3P 753020-82-5P 753020-83-6P
 753020-84-7P 844831-85-2P 844831-86-3P
 844831-88-5P 844831-89-6P 844831-92-1P
 844831-93-2P 844831-94-3P 844832-00-4P
 844832-01-5P 844832-02-6P 844832-04-8P
 844832-05-9P 844832-07-1P 844832-09-3P
 844832-10-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of indol-5-ylsulfonamide derivs. as 5-HT6 receptor modulators)


RN 753020-75-6 CAPLUS
 CN 1-Naphthalenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-
 (CA INDEX NAME)




RN 753020-76-7 CAPLUS
 CN 2-Naphthalenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-
 (CA INDEX NAME)




RN 753020-79-0 CAPLUS
 CN 1-Naphthalenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-2-methyl-1H-indol-5-yl]-
 (CA INDEX NAME)



RN 753020-80-3 CAPLUS
 CN 2-Naphthalenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-2-methyl-1H-indol-5-yl]-
 (CA INDEX NAME)




RN 753020-82-5 CAPLUS
 CN 1-Naphthalenesulfonamide, N-[1-[2-(diethylamino)ethyl]-1H-indol-5-yl]-
 (CA INDEX NAME)




RN 753020-83-6 CAPLUS

CN 2-Naphthalenesulfonamide, N-[1-[2-(diethylamino)ethyl]-1H-indol-5-yl]-
(CA INDEX NAME)




RN 753020-84-7 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-[1-[2-(diethylamino)ethyl]-1H-indol-5-yl]-
(CA INDEX NAME)




RN 844831-85-2 CAPLUS

CN 1-Naphthalenesulfonamide, 5-chloro-N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-
(CA INDEX NAME)




RN 844831-86-3 CAPLUS

CN Benzenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]- (CA
INDEX NAME)




RN 844831-88-5 CAPLUS

CN Benzenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-4-phenoxy-
(CA INDEX NAME)




RN 844831-89-6 CAPLUS

CN Benzenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-4-methyl-
(CA INDEX NAME)




RN 844831-92-1 CAPLUS

CN Benzenesulfonamide, 3,5-dichloro-N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-
(CA INDEX NAME)




RN 844831-93-2 CAPLUS

CN Benzenesulfonamide, 3-bromo-N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-
(CA INDEX NAME)




RN 844831-94-3 CAPLUS

CN Benzenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-2-nitro-
(CA INDEX NAME)




RN 844832-00-4 CAPLUS

CN Benzenesulfonamide, 4-acetyl-N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-
(CA INDEX NAME)




RN 844832-01-5 CAPLUS

CN Benzenesulfonamide, 4-bromo-N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-
(CA INDEX NAME)




RN 844832-02-6 CAPLUS

CN Benzenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-4-methoxy-
(CA INDEX NAME)




RN 844832-04-8 CAPLUS

CN Benzenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-4-nitro-
(CA INDEX NAME)




RN 844832-05-9 CAPLUS

CN Benzenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-4-fluoro-
(CA INDEX NAME)




RN 844832-07-1 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-[1-[2-(dimethylamino)ethyl]-2-methyl-1H-indol-5-yl]-
(CA INDEX NAME)




RN 844832-09-3 CAPLUS

CN Benzenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-2-methyl-1H-indol-5-yl]-
4-phenoxy- (CA INDEX NAME)



RN 844832-10-6 CAPLUS
 CN Benzenesulfonamide, 3,5-dichloro-N-[1-[2-(dimethylamino)ethyl]-2-methyl-1H-indol-5-yl]- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	37.50	216.99
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.80	-4.80

FILE 'REGISTRY' ENTERED AT 15:02:21 ON 04 JUN 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 JUN 2008 HIGHEST RN 1025148-33-7
 DICTIONARY FILE UPDATES: 3 JUN 2008 HIGHEST RN 1025148-33-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> S 844831-94-3/RN

L5 1 844831-94-3/RN


=> SET NOTICE 1 DISPLAY

NOTICE SET TO 1 U.S. DOLLAR FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=> D L5 SQIDE 1-

YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/(N):y
THE ESTIMATED COST FOR THIS REQUEST IS 6.65 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN
RN 844831-94-3 REGISTRY
CN Benzenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-2-nitro-
(CA INDEX NAME)
MF C18 H20 N4 O4 S
SR CA
LC STN Files: CA, CAPLUS, CASREACT, USPATFULL
DT.CA Caplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES
(Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> SET NOTICE LOGIN DISPLAY

NOTICE SET TO OFF FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=>

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.46	219.45
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-4.80

FILE 'REGISTRY' ENTERED AT 15:03:09 ON 04 JUN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 3 JUN 2008 HIGHEST RN 1025148-33-7
DICTIONARY FILE UPDATES: 3 JUN 2008 HIGHEST RN 1025148-33-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> s 15

L6 1 844831-94-3/RN

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.46	219.91
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-4.80

FILE 'CAPLUS' ENTERED AT 15:03:26 ON 04 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 4 Jun 2008 VOL 148 ISS 23
FILE LAST UPDATED: 3 Jun 2008 (20080603/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s 15

L7 3 L5

=> d ibib abs 17 1-3

L7 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:136598 CAPLUS

DOCUMENT NUMBER: 142:240323

TITLE: Active substance combination comprising a compound with NPY receptor affinity and a compound with 5-HT6 receptor affinity

INVENTOR(S): Torrens Jover, Antoni; Mas Prio, Josep; Dordal Zueras, Alberto; Codony Soler, Xavier; Merce Vidal, Ramon; Aurelio Castrillo Perez, Jose; Frigola Constanza, Jordi; Buschmann, Helmut-Heinrich

PATENT ASSIGNEE(S): Laboratorios del Esteve S. A., Spain

SOURCE: PCT Int. Appl., 427 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005014045	A1	20050217	WO 2004-EP8514	20040729
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
ES 2228268	A1	20050401	ES 2003-1815	20030730
ES 2228268	B1	20060701		
AU 2004262488	A1	20050217	AU 2004-262488	20040729
CA 2534099	A1	20050217	CA 2004-2534099	20040729
EP 1660131	A1	20060531	EP 2004-741321	20040729
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
MX 2006PA01230	A	20060515	MX 2006-PA1230	20060130
US 20070009597	A1	20070111	US 2006-566402	20060705
PRIORITY APPLN. INFO.:			ES 2003-1815	A 20030730
			WO 2004-EP8514	W 20040729
OTHER SOURCE(S):	CASREACT 142:240323; MARPAT 142:240323			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to an active substance combination comprising at least one compound I [R1-R4 = H, halo, alkyl, etc.; R5 = H, alkyl, (un)saturated cycloalkyl; R6-R9 = H, alkyl, (un)saturated cycloalkyl, etc.;

A = CHR18, CHR18CH2; B = alkyl, (un)saturated cycloalkyl, etc.; R10 = H, alkyl, (un)saturated cycloalkyl, etc.; R11 = alkyl, (un)saturated cycloalkyl, etc.; NR10R11 = (un)saturated heterocyclyl; R18 = H, alkyl, (un)saturated cycloalkyl, etc.] with neuropeptide Y-receptor affinity, preferably

neuropeptide Y5-receptor affinity, and at least one compound with 5-HT6 receptor affinity (such as II [R1 = H, alkyl, Ph, CH2PH; R2 = NR4R5, (un)saturated (hetero)cycloalkyl, etc.; R3 = H, alkyl; R4, R5 = H, alkyl; or NR4R5 = (un)saturated heterocyclyl; A = (un)substituted (hetero)aryl; n = 0-4]), a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament. Synthesis of amides I and sulfonamides such as II is described in examples. E.g., a multi-step synthesis of III.HCl, starting from 1-(tert-butoxycarbonyl)-4-piperidinone and Me anthranilate, was given. The amides I and sulfonamides such as II were tested against neuropeptide Y5 and 5-HT6 binding (data given for representative compds.).

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:136568 CAPLUS

DOCUMENT NUMBER: 142:240322

TITLE: Active substance combination comprising a compound with NPY receptor affinity and a compound with 5-HT6 receptor affinity

INVENTOR(S): Torrens Jover, Antoni; Mas Prio, Josep; Dordal Zueras, Alberto; Codony Soler, Xavier; Merce Vidal, Ramon; Aurelio Castrillo Perez, Jose; Frigola Constansa, Jordi; Buschmann, Helmut-Heinrich

PATENT ASSIGNEE(S): Laboratorios del Esteve S. A., Spain

SOURCE: PCT Int. Appl., 451 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005014000	A1	20050217	WO 2004-EP8515	20040729
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
ES 2228267	A1	20050401	ES 2003-1814	20030730
ES 2228267	B1	20060701		
AU 2004262489	A1	20050217	AU 2004-262489	20040729
CA 2534100	A1	20050217	CA 2004-2534100	20040729
EP 1648468	A1	20060426	EP 2004-763612	20040729
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
MX 2006PA01232	A	20060515	MX 2006-PA1232	20060130
US 20070059364	A1	20070315	US 2006-566100	20061026
PRIORITY APPLN. INFO.:			ES 2003-1814	A 20030730
			WO 2004-EP8515	W 20040729

OTHER SOURCE(S): MARPAT 142:240322

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to an active substance combination comprising at least one compound I [R1-R4 = H, halo, alkyl, etc.; R5 = H, alkyl, (un)saturated (hetero)cycloalkyl; R6-R9 = H, alkyl, (un)saturated (hetero)cycloalkyl, etc.; A = CHR18, CHR18CH2; R10 = H, alkyl, (un)saturated cycloalkyl, etc.; R11 = alkyl, (un)saturated cycloalkyl, etc.; NR10R11 = (un)saturated heterocyclyl; R18 = H, alkyl, (un)saturated cycloalkyl, etc.]

with

neuropeptide Y-receptor affinity, preferably neuropeptide Y5-receptor affinity, and at least one compound with 5-HT6 receptor affinity (such as II [R1 = H, alkyl, Ph, CH2PH; R2 = NR4R5, (un)saturated (hetero)cycloalkyl, etc.; R3 = H, alkyl; R4, R5 = H, alkyl; or NR4R5 = (un)saturated heterocyclyl; A = (un)substituted (hetero)aryl; n = 0-4]), a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament. Synthesis of amides I and sulfonamides such as II is described in examples. Thus, reacting 6-chloro-1-(4-piperidinyl)-1,4-dihydro-2H-3,1-benzoxazinone hydrochloride with 2-(2-chloroacetamide)-2',5-dichlorobenzophenone in the presence of K2CO3 in DMF followed by treating of the free base with HCl/EtOH afforded 61% III.HCl. The amides I and sulfonamides such as II were tested against neuropeptide Y5 and 5-HT6 binding (data given for representative compds.).

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:136549 CAPLUS

DOCUMENT NUMBER: 142:240310

TITLE: Preparation of indol-5-yl sulfonamide derivatives and their use as 5-HT6 modulators

INVENTOR(S): Merce Vidal, Ramon; Codony Soler, Xavier; Dordal Zuera, Alberto

PATENT ASSIGNEE(S): Laboratorios del Esteve S. A., Spain

SOURCE: PCT Int. Appl., 123 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2005013977	A1	20050217	WO 2004-EP8511	20040729
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
ES 2222827	A1	20050201	ES 2003-1805	20030730
ES 2222827	B1	20060301		
AU 2004262485	A1	20050217	AU 2004-262485	20040729
CA 2533976	A1	20050217	CA 2004-2533976	20040729
EP 1648445	A1	20060426	EP 2004-763610	20040729
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				

CN 1832740	A	20060913	CN 2004-80022472	20040729
BR 2004013110	A	20061003	BR 2004-13110	20040729
JP 2007500165	T	20070111	JP 2006-521529	20040729
MX 2006PA01159	A	20060424	MX 2006-PA1159	20060127
NO 2006000865	A	20060222	NO 2006-865	20060222
US 20070032520	A1	20070208	US 2006-566094	20061003
PRIORITY APPLN. INFO.:			ES 2003-1805	A 20030730
			WO 2004-EP8511	W 20040729
OTHER SOURCE(S):			CASREACT 142:240310; MARPAT 142:240310	
GI				



AB Title compds. I [R1 = NR8R9 radical or (un)saturated-(un)substituted cycloaliph. radical optionally containing at least one heteroatom; R2-4,6-7 independently = H, NO2, alkoxy, CN, etc.; R5 = H or (un)saturated alkyl optionally at least monosubstituted; R8 or R9 independently = H or (un)saturated alkyl optionally at least monosubstituted with provisions; or R8 and R9 together with the bridging N atom form a (un)saturated-(un)substituted heterocyclic ring; A = (un)substituted mono or polycyclic aromatic ring; n = 0-4] and their pharmaceutically acceptable salts are prepared and disclosed as 5-HT6 modulators. Thus, e.g., II, was prepared via reaction of naphthalene-2-sulfonyl chloride with 5-amino-1-(2-dimethylaminoethyl)-1H-indole. Selected data from 5-HT6 receptor binding studies revealed Ki values (nM) ranging from 1.89-112.4.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
9.21	229.12

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

CA SUBSCRIBER PRICE

-2.40

-7.20

STN INTERNATIONAL LOGOFF AT 15:04:16 ON 04 JUN 2008